Navigation Links
Children's National researchers develop novel anti-tumor vaccine
Date:10/2/2008

WASHINGTON, DCA novel anti-tumor vaccine for neuroblastoma and melanoma developed by scientists and clinicians at Children's National Medical Center in collaboration with investigators from the University of Iowa is showing significant impact on tumor growth in mice, according to new research published in the October edition of the research journal Cancer Immunology, Immunotherapy. The vaccine uses the tumor's own protein to induce an immune system response, allowing for a personalized approach to treatment.

The vaccine and delivery system, developed in the laboratory of Children's National Chief of General and Thoracic Surgery Anthony Sandler, MD, involves the creation of synthetic microparticles known as "immune stimulatory antigen loaded particles" (ISAPs), that consist of tumor antigens (proteins) from the specific tumor to be targeted, as well as immune stimulatory agents. The ISAPs are detected and engulfed by specialized immune cells and sensed to be immune-stimulating "foreign bodies."

The study shows that ISAPs are effective at blocking the growth of tumors in mice by inducing activation of immune cells that then stimulate the immune system to specifically target the tumor whose antigens match those that are loaded in the particles known as tumor specific immunity.

The research team also discovered, however, that the impact of ISAPs on tumor growth was partially mitigated by an increased presence of regulatory t-cells (T-reg) when ISAPs are introduced into the body. The researchers believe that T-regs play a key role in how the vaccine impacts tumor growth by suppressing the development of the specific immune cells needed to combat the tumor. By adding a T-reg suppressor such as cyclosphosphamide or anti-CD25 antibody, the scientists were able to have a greater impact on preventing tumor growth using the ISAP approach.

"For tumors like neuroblastoma, reduction to minimal residual disease with standard therapies like chemotherapy and/or surgical resection and subsequent treatment with this vaccine could quite possibly cure the patient of the disease in the not too distant future," said Dr. Sandler, lead author of the study. "Creation of ISAPs allows us to target our treatments to the specific tumor of interest, a capability that will more effectively combat a wide range of these tumors in a personalized fashion."


'/>"/>

Contact: Jennifer Leischer
jleische@cnmc.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Related biology news :

1. Wolves find happy hunting grounds in Yellowstone National Park
2. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
3. ESMO International Symposium on Immunology
4. Story tips from the US Department of Energys Oak Ridge National Laboratory, September 2007
5. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
6. Director of National Intelligence to Speak at Conference
7. Singapore National Science and Technology Awards
8. Conservation International and Toyota partner to protect Philippines rain forests
9. International team shows mercury concentrations in fish respond quickly to increased deposition
10. International team shows mercury concentrations in fish respond quickly to increased deposition
11. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2020)... ... July 21, 2020 , ... USDM Life ... and compliance, announces a new solution to manage regulated workloads on Microsoft Azure. ... their technology stack complies with FDA and global regulations. USDM's new managed service ...
(Date:7/10/2020)... FALLS CHURCH, Va. (PRWEB) , ... July 08, ... ... , The Latest on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, ... product may need a comparability study, but what is the most effective way ...
(Date:7/2/2020)... REDWOOD CITY, Calif. (PRWEB) , ... July 01, ... ... stage biotech company, presented its phase 1a findings of Neihulizumab, a biologic for ... annual conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... August 03, 2020 , ... ... announced Jim Corrigan, President and CEO has been named one of the 100 ... of industry sectors, PharmaVoice 100 honorees are selected based on how they have ...
(Date:7/31/2020)... ... 29, 2020 , ... G-CON Manufacturing, the leader in off-site ... FOR LIFE.” The adoption of this taglines comes at a time of tremendous ... to provide patients with urgently needed vaccines and other lifesaving pharmaceutical treatments. G-CON’s ...
(Date:7/31/2020)... , ... July 29, 2020 , ... ... Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions ... that they have entered into a strategic partnership whereby Catalent will provide support ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... the life sciences industry, today announced the release of its signature product ... Medical Science Liaisons (MSLs) and other field medical professionals. , Beacon ...
Breaking Biology Technology: